The ILCN is aware that the situation with telehealth differs across regions and that lack of access to technology is a huge obstacle. We would love to hear from IASLC members around the globe about your experiences. Please email us at [email protected]. Read more
Most cancer immunotherapies currently in development aim to stimulate antitumor T-cell responses either by adoptive transfer of in vitro expanded native or genetically modified T lymphocytes targeting malignant cells,1 ,2 […] Read more
Since December 2019, the world has been mired in a pandemic that has displaced other 21st-century health priorities for many populations. The social significance and speed of contagion from COVID-19 […] Read more
Surgical resection is the most effective treatment for patients with early-stage NSCLC.1 However, approximately 25% of these patients do not undergo resection, usually because of underlying comorbidities precluding surgery or […] Read more
CheckMate-816 made quite a splash at both the AACR Annual Meeting 2021 and the 2021 ASCO Annual Meeting’s virtual podium, and the accompanying article by Patrick Forde, MD, explains why. Dr. Forde, who is director of the Thoracic Oncology Clinical Research Program and associate professor of Oncology at Johns Hopkins... Read more
Platinum-based chemotherapy, given either before (neoadjuvant) or after (adjuvant) surgery for stage II and III NSCLC is associated with a 5% improvement in long-term survival. Despite consensus guidelines recommending its […] Read more
The Lung Master Protocol (Lung-MAP; S1400) was a biomarker-driven master protocol. This trial was originally designed to address the relative paucity of effective, targeted therapies in squamous cell lung cancer, […] Read more
The growth of these domestic drugs should shine a light on the lack of diversity in many international clinical trials in immunotherapy. Read more
Despite U.S. Food and Drug Administration (FDA) approvals for the addition of anti–programmed death-ligand 1 (PD-L1) therapies to a first-line combination of etoposide plus a platinum-based agent for extensive-stage small […] Read more
The U.S. National Cancer Institute (NCI) Cancer Moonshot Biobank launched in September 2020, with the aim of accelerating cancer research by creating a resource of well-annotated, longitudinal cancer biospecimens from […] Read more